---

Urine LAM Test for Tuberculosis — Complete MD Exam Answer (10 Marks)

---

1. Introduction

---

2. The Antigen: Lipoarabinomannan (LAM)

• LAM is a heat-stable lipoglycan (glycolipid) embedded in the mycobacterial cell wall
• It is shed into urine by both metabolically active and dead/damaged mycobacterial cells
• It reaches the urine via the bloodstream and is filtered by the kidney, making urine a suitable non-invasive sample
• Because LAM is renally cleared, urinary LAM levels correlate with mycobacterial burden and inversely correlate with CD4+ T-cell count (more antigen shed with greater immune suppression)

---

3. The Test — Alere Determine TB LAM Ag Test (AlereLAM)

How to Read

• Positive: Both C and T bands visible (any shade of T band)
• Negative: Only C band visible
• Invalid: No C band

---

4. WHO Recommendations (Updated Guidelines)

Inpatient Settings (HIV-positive adults and children):

• Who have signs and symptoms of TB, OR
• Have advanced HIV disease or are seriously ill, OR
• Irrespective of symptoms, have a CD4 count ≤200 cells/µL

Outpatient Settings (HIV-positive adults and children):

• Who have signs and symptoms of TB, OR
• Irrespective of symptoms, have a CD4 count <100 cells/µL

"The WHO recommends that this assay be used to assist in the diagnosis of TB only in HIV-positive adults and children..." — Harrison's Principles of Internal Medicine 22e, 2025

• HIV-negative individuals (very low sensitivity)
• General population TB screening
• Pulmonary TB diagnosis in the absence of HIV

---

5. Diagnostic Performance

Why sensitivity varies with CD4 count:

• Low CD4 → High mycobacterial burden → more LAM shed → higher sensitivity
• High CD4 → Contained infection, lower bacillary load → less urinary LAM

2023 Lancet Global Health Meta-analysis (Broger et al., PMID 37202025):

• Analyzed 10,202 participants (20 datasets), PLWH aged ≥15 years
• AlereLAM diagnostic yield: 41% vs Xpert MTB/RIF yield: 61%
• Crucial finding: Among hospitalized, unselected inpatients, only 54% could provide sputum vs 99% provided urine
• AlereLAM + Xpert combined yield = 71% in unselected inpatients
• Conclusion: AlereLAM should be prioritized to inform TB therapy among HIV-positive inpatients regardless of symptoms or CD4 count, because sputum-based tests are undermined by inability to produce sputum

---

6. Advantages of the Test

1. Non-sputum based — critical for severely ill patients who cannot produce sputum
2. Rapid result — within 25–30 minutes (vs. culture: 2–8 weeks)
3. Point-of-care — no laboratory infrastructure needed
4. Detects extra-pulmonary TB (disseminated, miliary TB) — LAM enters blood and urine even without pulmonary involvement
5. Safe sample collection — urine avoids aerosol generation and transmission risk from sputum
6. Detects antigen from dead bacilli — remains positive even after starting therapy
7. Inexpensive — suitable for resource-limited settings in Sub-Saharan Africa and South Asia

---

7. Limitations

1. Low sensitivity in HIV-negative patients → not indicated outside HIV
2. Sensitivity declines markedly with CD4 >200 cells/µL
3. Cannot distinguish active TB from non-tuberculous mycobacterial (NTM) infection
4. False positives possible in other mycobacterial infections (M. avium complex shares LAM structure)
5. Not FDA-approved for use in the United States
6. Cannot assess drug resistance — no information on rifampicin or isoniazid resistance
7. Grading is subjective — visual reading can be variable without a dedicated reader
8. Not recommended for monitoring treatment response

---

8. Clinical Utility / Role in Algorithm

HIV-positive patient, severely ill or CD4 <100/200 cells/µL
             ↓
     Obtain URINE + SPUTUM simultaneously
             ↓
  LF-LAM (urine)  +  Xpert MTB/RIF (sputum)
             ↓                    ↓
    Result in 30 min         Result in 2 hrs
             ↓
   Combined yield ~71% — initiate TB treatment if either positive

---

9. Newer Generation — FujiLAM

• Developed by Fujifilm (Japan)
• Uses nano-colloidal gold with higher avidity antibody → improved sensitivity (~70%) vs AlereLAM (~56%) at CD4 ≤100 cells/µL
• WHO-approved (2020 policy update)
• Particularly useful in childhood TB (systematic review, Olbrich et al. 2022, PMID 36053609)
• Higher sensitivity but similar specificity

---

10. Comparison with Other TB Diagnostics

---

11. Summary Points for Exam

---

Key References

• Harrison's Principles of Internal Medicine, 22nd ed. (2025) — LF-LAM WHO indications
• Murray & Nadel's Textbook of Respiratory Medicine — Sensitivity/specificity meta-analysis (56%/90% at CD4 ≤100)
• Fishman's Pulmonary Diseases and Disorders — Point-of-care urine antigen detection
• Tietz Textbook of Laboratory Medicine, 7th ed. — Alere Determine TB LAM Ag test description
• Broger T et al. Lancet Glob Health 2023 [PMID: 37202025] — IPD meta-analysis, AlereLAM yield 41%, combined yield 71%